Pharmafile Logo
Pharmafocus logo
Advanced Search

England isn’t the sick man of Europe

January 27, 2011
Kings Fund, NHS, NHS reform, king's fund

A leading health economist has questioned claims by the health secretary Andrew Lansley that England’s health is lagging behind other …

News
Pfizer France Twitter

Digital Pharma: Pfizer expands European Twitter use

January 27, 2011
Medical Communications Digital Pharma blog, Pfizer, Twitter

Pfizer has expanded its use of Twitter with its French operations becoming the latest of its European subsidiaries to join …

News

Bertil Lindmark joins Almirall as R&D head

January 27, 2011
Research and Development Almirall, Bertil Lindmark, appointment, research and development

Almirall has appointed Bertil Lindmark as executive director of R&D following the retirement of Dr Per-Olof Andersson. Bertil joins the …

Appointment

Lilly Oncology chief resigns

January 27, 2011
Research and Development, Sales and Marketing Eli Lilly, John Johnson, Lilly Oncology, appointment, lilly, research and development, sales and marketing

Lilly has an unexpected search on its hands for someone to lead its oncology business after John Johnson unexpectedly announced …

News

Novartis posts strong growth but warns of tough year ahead

January 27, 2011
Sales and Marketing 2010 pharma results, Novartis

Novartis has posted strong sales growth for the full year but its chief executive warns of ‘headwinds in 2011’ as …

News

Prime Minister uses online network to rally doctors around reforms

January 27, 2011
Sales and Marketing Doctors.net.uk, GPs, commissioning, david cameron, docotrs, prime minister

 Prime Minister David Cameron has made exclusive use of Doctors.net.uk, the UK’s largest network of medical professionals, to reinforce his …

News
Press release

NICE decides to back Abilify in schizophrenia

January 27, 2011
Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia

NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …

News

Double Helix Consulting expands

January 26, 2011
Sales and Marketing Clara Loveman, Double Helix, Dr Clive Whitcher, Dr Laurence Wild, appointment, sales and marketing

Double Helix Consulting has appointed three new executives to its growing global team – Clara Loveman, Dr Clive Whitcher and …

Appointment

The Evolving Role of European Regulatory Agencies

January 26, 2011
Research and Development Consultancy, regulatory affairs, regulatory agencies

The regulatory landscape can change in a very short period of time. Matthew Walker, Senior Regulatory Affairs Executive at TRAC …

Feature
Thought Leadership

Pharma-biotech partnerships: creative approaches to doing the deal

January 26, 2011
Research and Development Susan Aldridge, biotech, biotech partnerships, pharma partnering

Research and development partnerships between big pharma and the biotech sector are now a vital component in bringing new medicines …

Feature

Sanofi buys into cancer antibody research

January 26, 2011
Research and Development Cancer, Oxford Biotherapeutics, Sanofi, Sanofi-Aventis, antibody drug conjugate, cancer research

Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) oncology programmes. For an undisclosed …

News

J&J posts negative growth as pharma sales stall

January 26, 2011
Sales and Marketing 2010 pharma results, J&J, JJ, Johnson and Johnson, Remicade, Risperdal Consta

Falling fourth quarter sales of Risperdal Consta and Remicade capped a year to forget for Johnson and Johnson. The company’s …

News

Dr Marie-Paule Richard joins AiCuris as CMO

January 26, 2011
Research and Development AiCuris, Dr Marie-Paule Richard, appointment, research and development

German clinical research company AiCuris has appointed Dr Marie-Paule Richard as chief medical officer. She has over 24 years of …

Appointment

Eisai sepsis drug fails in phase III

January 26, 2011
Research and Development, Sales and Marketing Eisai, eritoran, perampanel, sepsis

A new treatment for severe sepsis could be abandoned entirely after phase III results fell short. Eisai’s eritoran did not …

News

NHS competition will prevent postcode lottery, says Lansley

January 25, 2011
NHS, NHS reforms, postcode prescribing

The government has pledged that value-based competition in the NHS will create “the very opposite of the postcode lottery”, following …

News
Amgen HQ

Amgen signs $1 billion cancer biotech deal

January 25, 2011
Research and Development Amgen, BioVex, OncoVEXGM-CSF, cancer vaccine

Amgen is set to pay $1 billion for US biotech firm BioVex, in the process gaining access to its novel …

News

David Jukes promoted to president of Univar Europe

January 25, 2011
Manufacturing and Production David Jukes, John van Osch, manufacturing and production, univar

Chemical distributor Univar has promoted David Jukes to president of its European operations. He replaces John van Osch who is …

Appointment

Genzyme plans new Belgium facility

January 25, 2011
Manufacturing and Production Belgium, Genzyme, Lumizyme, Myozyme, Pompe disease, Sanofi-Aventis, alglucosidase alfa

US rare disease drug specialist Genzyme, the subject of a hostile takeover offer from France’s Sanofi-Aventis, says that it will …

News

Bio and clinical plants feature in 2011 FOYA honours

January 25, 2011
Manufacturing and Production MedImmune, Merck & Co, Novartis, Pfizer, Roche, Shire HGT, pharma manufacturing

Three US and three European manufacturing plants have been shortlisted for the annual Facility of the Year awards, with the …

News
GlaxoSmitKline's headquarters

GSK skin cancer drugs moves into phase III

January 25, 2011
Research and Development BRAF V600 mutation, Cancer, Duchenne Muscular Dystrophy, GSK, GSK1120212, GSK2118436, GSK968, GlaxoSmithKline, melanoma, skin cancer

GlaxoSmithKline has begun late-stage trials of two new drugs for advanced or metastatic melanoma patients. GSK2118436 and GSK1120212 are being …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026